FDA approves new oral drug to relieve constipation from opioid painkillers

Share this article:
Long-term care residents who experience constipation from taking opioids to manage chronic pain may benefit from Amitiza, an oral drug recently approved by the Food and Drug Administration.

Amitiza (lubiprostone) has already been approved in the United States for other conditions, such as constipation-related irritable bowel syndrome. Manufactured by Sucampo Pharmaceuticals Inc./Takeda Pharmaceuticals USA Inc., it is the first oral drug to relieve constipation caused by opioid therapy for managing noncancer pain.

Constipation is a common side effect for people who take oxycodone, fentanyl or other opioids on a long-term basis. Amitiza was approved by the FDA based on 12-week studies of people on these painkillers.

The drug's effectiveness when taken with diphenylheptane opioids, such as methadone, has not been established, according to the manufacturer. The company also warned that lubiprostone should not be taken by anyone with impaired liver function.

Share this article:

More in News

Skilled nursing facility trends contribute to improved Medicare outlook, Congressional report says

The Medicare trust fund is on track to remain solvent until 2030, trustees of the program stated in a Congressional report released Monday. This improved outlook is due in part to revised expectations about the case mix in skilled nursing facilities.

House bill would define, promote coordinated long-term care services

A bill introduced in the House of Representatives would target improved care coordination for seniors, also adding it under the Older Americans Act.

Seize the day: Tech Awards deadline is tomorrow

Seize the day: Tech Awards deadline is tomorrow

The final countdown has begun: Long-term care providers have less than 48 hours to enter the third annual McKnight's Excellence in Technology Awards. Submissions will be accepted through July 30.